Quantifying Clinical Trial Diversity of FDA Novel Drug Approvals

William E Fitzsimmons, Muhammed Y Idris, Priscilla Pemu
doi: https://doi.org/10.1101/2023.05.11.23289884

Article Information

doi 
https://doi.org/10.1101/2023.05.11.23289884
History 
  • May 16, 2023.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. William E Fitzsimmons, Pharm.D., M.S.1,3,*,
  2. Muhammed Y Idris, Ph.D.2,3 and
  3. Priscilla Pemu, MD2
  1. 1University of Illinois at Chicago Colleges of Pharmacy and Medicine, Chicago, IL, USA
  2. 2Clinical Research Center, Morehouse School of Medicine, Atlanta, GA, USA
  3. 3CARER Group, San Diego, CA, USA
  1. ↵*Corresponding Author: William E. Fitzsimmons, Pharm.D., M.S., University of Illinois at Chicago, 833 S. Wood St., Chicago, IL 60607 wfitzsim{at}uic.edu
Back to top
Posted May 16, 2023.
Download PDF

Supplementary Material

Data/Code
Email
Quantifying Clinical Trial Diversity of FDA Novel Drug Approvals
William E Fitzsimmons, Muhammed Y Idris, Priscilla Pemu
medRxiv 2023.05.11.23289884; doi: https://doi.org/10.1101/2023.05.11.23289884
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area